Renovaro Inc. Appoints New Director
Ticker: LNAI · Form: 8-K · Filed: Jul 3, 2024 · CIK: 1527728
| Field | Detail |
|---|---|
| Company | Renovaro Inc. (LNAI) |
| Form Type | 8-K |
| Filed Date | Jul 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, management-change
TL;DR
Renovaro adds Dr. Jonathan L. Cohen to the board.
AI Summary
Renovaro Inc. announced on June 27, 2024, a change in its board of directors. Dr. Jonathan L. Cohen has been appointed as a new director, effective immediately. This appointment is part of the company's ongoing efforts to strengthen its leadership and strategic direction.
Why It Matters
The addition of a new director can signal a shift in strategy or a focus on specific expertise that may impact the company's future performance and direction.
Risk Assessment
Risk Level: low — The filing reports a routine board appointment, which typically carries low immediate risk.
Key Players & Entities
- Renovaro Inc. (company) — Registrant
- Dr. Jonathan L. Cohen (person) — Newly appointed director
- June 27, 2024 (date) — Effective date of appointment
FAQ
Who has been appointed to the board of directors at Renovaro Inc.?
Dr. Jonathan L. Cohen has been appointed as a new director.
When was the appointment of the new director effective?
The appointment was effective as of June 27, 2024.
What is the exact name of the company filing this report?
The exact name of the registrant is Renovaro Inc.
In which state was Renovaro Inc. incorporated?
Renovaro Inc. was incorporated in Delaware.
What is the Commission File Number for Renovaro Inc.?
The Commission File Number for Renovaro Inc. is 000-54478.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2024-07-03 16:31:02
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar
Filing Documents
- e5799_8k.htm (8-K) — 27KB
- 0001731122-24-001085.txt ( ) — 196KB
- renb-20240627.xsd (EX-101.SCH) — 3KB
- renb-20240627_lab.xml (EX-101.LAB) — 33KB
- renb-20240627_pre.xml (EX-101.PRE) — 22KB
- e5799_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO INC. By: /s/ Mark Dybul Name: Mark Dybul, M.D. Title: Chief Executive Officer Date: July 3, 2024 3